The global infection control market is expected to reach more than $258 billion (U.S.) by 2025, according to a new report by Grand View Research.
Concern regarding the surge in hospital acquired infections is driving the market, making room for more infection control products. The resulting demand for sterilized formulations and new biologics are key growth factors.
Healthcare organizations are implementing strategies for early recognition, reporting, isolation and surveillance of disease incidents that are a public health concern.
Additionally, more intensive training modules for nurses and other medical staff on infection prevention and control is expected to add a high potential for more usage of infection control products.
For example, the College of Nurses of Ontario released guidelines concerning standard practices for maintaining hand hygiene to reduce contamination and the spread of infection. In the U.S., the Centers for Disease Control and Prevention (CDC) has released guidelines for disinfection and sterilization for efficient use of infection control products by healthcare personnel in wide array of healthcare settings.
A higher penetration rate of these products is anticipated to fuel market demand and revenue. North America has already captured a dominant share of the overall infection control market owing to extensive infection prevention activities being implemented in hospitals, medical device and pharmaceutical companies.
Meanwhile, the market in Asia Pacific is projected to see exponential growth during the forecast period as a result of increasing awareness of the spread of infections within healthcare settings and measures for prevention.